Is administration of the HPV vaccine during pregnancy feasible in the future?

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite the strong evidence supporting the efficacy of the HPV vaccine, the uptake rate remains low. One reason for this is that young females do not interact frequently with the healthcare system. In fact, pregnancy is often the first time young women experience multiple scheduled visits to a health provider. We review the data regarding safety of administering the HPV vaccine during pregnancy and consider the possibility of incorporating vaccination into prenatal care. Although the optimal time for vaccination is prior to sexual debut, this does not always occur, and as such, a broader approach to HPV vaccination may be necessary. Increasing the vaccine uptake rate among young women who did not initiate or complete the series earlier may significantly contribute to the decline in HPV-associated diseases.

Original languageEnglish (US)
Pages (from-to)213-219
Number of pages7
JournalExpert Review of Vaccines
Volume13
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Papillomavirus Vaccines
Vaccination
Pregnancy
Prenatal Care
Vaccines
Delivery of Health Care
Safety
Health

Keywords

  • HPV vaccine
  • pregnancy
  • vaccine administration
  • young women

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Is administration of the HPV vaccine during pregnancy feasible in the future? / Berenson, Abbey; Patel, Pooja; Barrett, Alan.

In: Expert Review of Vaccines, Vol. 13, No. 2, 02.2014, p. 213-219.

Research output: Contribution to journalArticle

@article{8019a16455f14aa998ea86eed86d719e,
title = "Is administration of the HPV vaccine during pregnancy feasible in the future?",
abstract = "Despite the strong evidence supporting the efficacy of the HPV vaccine, the uptake rate remains low. One reason for this is that young females do not interact frequently with the healthcare system. In fact, pregnancy is often the first time young women experience multiple scheduled visits to a health provider. We review the data regarding safety of administering the HPV vaccine during pregnancy and consider the possibility of incorporating vaccination into prenatal care. Although the optimal time for vaccination is prior to sexual debut, this does not always occur, and as such, a broader approach to HPV vaccination may be necessary. Increasing the vaccine uptake rate among young women who did not initiate or complete the series earlier may significantly contribute to the decline in HPV-associated diseases.",
keywords = "HPV vaccine, pregnancy, vaccine administration, young women",
author = "Abbey Berenson and Pooja Patel and Alan Barrett",
year = "2014",
month = "2",
doi = "10.1586/14760584.2014.867236",
language = "English (US)",
volume = "13",
pages = "213--219",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Is administration of the HPV vaccine during pregnancy feasible in the future?

AU - Berenson, Abbey

AU - Patel, Pooja

AU - Barrett, Alan

PY - 2014/2

Y1 - 2014/2

N2 - Despite the strong evidence supporting the efficacy of the HPV vaccine, the uptake rate remains low. One reason for this is that young females do not interact frequently with the healthcare system. In fact, pregnancy is often the first time young women experience multiple scheduled visits to a health provider. We review the data regarding safety of administering the HPV vaccine during pregnancy and consider the possibility of incorporating vaccination into prenatal care. Although the optimal time for vaccination is prior to sexual debut, this does not always occur, and as such, a broader approach to HPV vaccination may be necessary. Increasing the vaccine uptake rate among young women who did not initiate or complete the series earlier may significantly contribute to the decline in HPV-associated diseases.

AB - Despite the strong evidence supporting the efficacy of the HPV vaccine, the uptake rate remains low. One reason for this is that young females do not interact frequently with the healthcare system. In fact, pregnancy is often the first time young women experience multiple scheduled visits to a health provider. We review the data regarding safety of administering the HPV vaccine during pregnancy and consider the possibility of incorporating vaccination into prenatal care. Although the optimal time for vaccination is prior to sexual debut, this does not always occur, and as such, a broader approach to HPV vaccination may be necessary. Increasing the vaccine uptake rate among young women who did not initiate or complete the series earlier may significantly contribute to the decline in HPV-associated diseases.

KW - HPV vaccine

KW - pregnancy

KW - vaccine administration

KW - young women

UR - http://www.scopus.com/inward/record.url?scp=84893116504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893116504&partnerID=8YFLogxK

U2 - 10.1586/14760584.2014.867236

DO - 10.1586/14760584.2014.867236

M3 - Article

VL - 13

SP - 213

EP - 219

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 2

ER -